Shinji Furuya1, Josepmaria Argemi2, Takeki Uehara3, Yuuki Katou3, Derrick E Fouts4, Bernd Schnabl5, Laurent Dubuquoy6, Abha Belorkar7, Rajanikanth Vadigepalli7, Hiroshi Kono8, Ramon Bataller2, Ivan Rusyn1. 1. From the , Department of Veterinary Integrative Biosciences (SF, IR), Texas A&M University, College Station, Texas. 2. Center for Liver Diseases, (JA, RB), Pittsburgh Research Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 3. Laboratory of Veterinary Pathology, (TU, YK), Osaka Prefecture University, Osaka, Japan. 4. J. Craig Venter Institute, (DEF), Rockville, Maryland. 5. Department of Medicine, (BS), University of California San Diego, La Jolla, California. 6. Unité INSERM 995, (LD), Faculté de Médecine, Hôpital Huriez, Lille Service des Maladies de l'Appareil Digestif, Lille, France. 7. Department of Pathology, Anatomy and Cell Biology, (AB, RV), Thomas Jefferson University, Philadelphia, Pennsylvania. 8. First Department of Surgery, (HK), University of Yamanashi, Yamanashi Prefecture, Japan.
Abstract
BACKGROUND: Alcohol-related liver disease is the main cause of liver-related mortality worldwide. The development of novel targeted therapies for patients with advanced forms (i.e., alcoholic hepatitis, AH) is hampered by the lack of suitable animal models. Here, we developed a novel mouse model of acute-on-chronic alcohol liver injury with cholestasis and fibrosis and performed an extensive molecular comparative analysis with human AH. METHODS: For the mouse model of acute-on-chronic liver injury, we used 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC, 0.05% w/w) diet for 8 weeks to establish cholestatic liver fibrosis. After 1-week washout period, male mice were fed intragastrically for 4 weeks with up to 24 g/kg of ethyl alcohol in a high-fat diet. This animal model was phenotyped using histopathology, clinical chemistry, microbiome, and gene expression approaches. Data were compared to the phenotypes of human alcohol-related liver disease, including AH. RESULTS: Mice with cholestatic liver fibrosis and subsequent alcohol exposure (DDC + EtOH) exhibited exacerbated liver fibrosis with a pericellular pattern, increased neutrophil infiltration, and ductular proliferation, all characteristics of human AH. DDC administration had no effect on urine alcohol concentration or liver steatosis. Importantly, DDC- and alcohol-treated mice showed a transcriptomic signature that resembled that of patients with AH. Finally, we show that mice in the DDC + EtOH group had an increased gut barrier dysfunction, mimicking an important pathophysiological mechanism of human AH. CONCLUSIONS: We developed a novel mouse model of acute-on-chronic cholestatic alcoholic liver injury that has considerable translational potential and can be used to test novel therapeutic modalities for AH.
BACKGROUND: Alcohol-related liver disease is the main cause of liver-related mortality worldwide. The development of novel targeted therapies for patients with advanced forms (i.e., alcoholic hepatitis, AH) is hampered by the lack of suitable animal models. Here, we developed a novel mouse model of acute-on-chronic alcohol liver injury with cholestasis and fibrosis and performed an extensive molecular comparative analysis with human AH. METHODS: For the mouse model of acute-on-chronic liver injury, we used 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC, 0.05% w/w) diet for 8 weeks to establish cholestatic liver fibrosis. After 1-week washout period, male mice were fed intragastrically for 4 weeks with up to 24 g/kg of ethyl alcohol in a high-fat diet. This animal model was phenotyped using histopathology, clinical chemistry, microbiome, and gene expression approaches. Data were compared to the phenotypes of human alcohol-related liver disease, including AH. RESULTS: Mice with cholestatic liver fibrosis and subsequent alcohol exposure (DDC + EtOH) exhibited exacerbated liver fibrosis with a pericellular pattern, increased neutrophil infiltration, and ductular proliferation, all characteristics of human AH. DDC administration had no effect on urine alcohol concentration or liver steatosis. Importantly, DDC- and alcohol-treated mice showed a transcriptomic signature that resembled that of patients with AH. Finally, we show that mice in the DDC + EtOH group had an increased gut barrier dysfunction, mimicking an important pathophysiological mechanism of human AH. CONCLUSIONS: We developed a novel mouse model of acute-on-chronic cholestatic alcoholic liver injury that has considerable translational potential and can be used to test novel therapeutic modalities for AH.
Authors: Matthew E Ritchie; Belinda Phipson; Di Wu; Yifang Hu; Charity W Law; Wei Shi; Gordon K Smyth Journal: Nucleic Acids Res Date: 2015-01-20 Impact factor: 16.971
Authors: Josepmaria Argemi; Maria U Latasa; Stephen R Atkinson; Ilya O Blokhin; Veronica Massey; Joel P Gue; Joaquin Cabezas; Juan J Lozano; Derek Van Booven; Aaron Bell; Sheng Cao; Lawrence A Vernetti; Juan P Arab; Meritxell Ventura-Cots; Lia R Edmunds; Constantino Fondevilla; Peter Stärkel; Laurent Dubuquoy; Alexandre Louvet; Gemma Odena; Juan L Gomez; Tomas Aragon; Jose Altamirano; Juan Caballeria; Michael J Jurczak; D Lansing Taylor; Carmen Berasain; Claes Wahlestedt; Satdarshan P Monga; Marsha Y Morgan; Pau Sancho-Bru; Philippe Mathurin; Shinji Furuya; Carolin Lackner; Ivan Rusyn; Vijay H Shah; Mark R Thursz; Jelena Mann; Matias A Avila; Ramon Bataller Journal: Nat Commun Date: 2019-07-16 Impact factor: 14.919